Melatonin Enhances the Effect of ABT-737 in Acute Monocytic Leukemia THP-1 Cells

A. I. Lomovsky,Y. L. Baburina,R. S. Fadeev,M. I. Kobyakova,Ya. V. Lomovskaya,R. R. Krestinin,L. D. Sotnikova,O. V. Krestinina
DOI: https://doi.org/10.1134/s002689332401014x
2024-03-08
Molecular Biology
Abstract:Melatonin ( N -acetyl-5-methoxytryptamine, MEL) is a hormone synthesized by the pineal gland. Due to its oncostatic effect, it can be considered as an antitumor agent and used for combination therapy. ABT-737, a Bcl-2 inhibitor, promotes cell death after treatment with agents that induce pro-apoptotic signals. In the present study, the combined effect of MEL and ABT-737 on changes in proliferative and mitotic activity, mitochondrial membrane potential, intracellular production of reactive oxygen species (ROS), and cytosolic Ca 2+ was studied. Moreover, changes in the expression of anti- and pro-apoptotic proteins (Bcl-2 and Bax), autophagy markers (LC3A/B (I, II)), endoplasmic reticulum stress markers (chaperones BIP and PDI, CHOP) were studied under these conditions. The effect of MEL together with ABT-737 led to an increase in the level of cytosolic Ca 2+ , intracellular production of ROS and a decrease in the membrane potential of mitochondria. The content of Bcl-2 increased, while the level of Bax decreased. Activation of CHOP stimulated autophagy and led to a decrease in the synthesis of chaperones BIP and PDI. It is assumed that melatonin can enhance the effect of other chemotherapeutic agents and can be used in the treatment of tumors.
biochemistry & molecular biology
What problem does this paper attempt to address?